SCHEMBL240773

SCHEMBL240773

CSc1ncc(C(=O)O)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
HSD17B10 Q99714 2/20 0.52
KDM4E B2RXH2 2/20 0.52
ALOX15 P16050 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
P4HA1 P13674 2/20 0.45
P4HTM Q9NXG6 2/20 0.45
HCAR2 Q8TDS4 1/20 0.44
MAPT P10636 1/20 0.44
MIF P14174 1/20 0.43
HCAR3 P49019 3/20 0.42
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL28006349 1.00 ALDH1A1 (0.52) ALDH1A1HSD17B10KDM4EALOX15MEN1
Hydrochloric Acid SCHEMBL5140518 0.98 ALDH1A1 (0.50) ALDH1A1HSD17B10KDM4EALOX15MEN1
Cyclopentanamine SCHEMBL28133408 0.83 HCAR3 (0.41) ALDH1A1HSD17B10KDM4EALOX15MEN1
SCHEMBL5406973 0.82 RAB9A (0.45) ALDH1A1KDM4EMEN1KMT2AHPGD
SCHEMBL28134267 0.81 PLK1 (0.50) MEN1KMT2AHPGD
SCHEMBL22551272 0.81 CSNK2A1 (0.48) HSD17B10MEN1KMT2A
SCHEMBL28700190 0.80 MEN1 (0.46) ALDH1A1HSD17B10KDM4EALOX15MEN1
SCHEMBL883870 0.80 NNMT (0.45) KDM4EMEN1KMT2A
SCHEMBL2820710 0.78 MEN1 (0.41) ALDH1A1KDM4EMEN1KMT2AP4HTM
Hydrochloric Acid SCHEMBL5140517 0.78 MEN1 (0.44) ALDH1A1KDM4EMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2635567-B1 INDOLE DERIVATIVES RICHTER GEDEON NYRT (HU) 2015-10-28 EP claimed
EP-2635567-A1 INDOLE DERIVATIVES Richter Gedeon Nyrt. (HU) 2013-09-11 EP claimed
US-20130217702-A1 INDOLE DERIVATIVES RICHTER GEDEON NYRT. 2013-08-22 US claimed
WO-2012059776-A1 INDOLE DERIVATIVES RICHTER GEDEON NYRT. (HU) 2012-05-10 WO claimed
EP-4748843-A2 ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2026-05-27 EP disclosed
CN-122080121-A Linker and use thereof in ligand drug conjugates 2026-05-26 CN disclosed
EP-4684807-A1 LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE Duality Biologics (Shanghai) Co., Ltd. (CN) 2026-01-28 EP disclosed
EP-4626864-A1 LINEAR HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS Protego Biopharma, Inc. (US) 2025-10-08 EP disclosed
EP-4556026-A1 ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2025-05-21 EP disclosed
EP-4552654-A1 ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2025-05-14 EP disclosed
CN-119564878-A Bioactive substance conjugate, preparation method and application thereof 苏州宜联生物医药有限公司 2025-03-07 CN disclosed
CN-119504997-A Bioactive substance conjugate, preparation method and application thereof 苏州宜联生物医药有限公司 2025-02-25 CN disclosed
CN-1150195-C Bicyclic nitrogen heterocycles - 2004-05-19 CN disclosed
EP-1361879-A1 2,4-DISUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-11-19 EP disclosed
WO-2003092686-A1 INHIBITORS OF HISTONE DEACETYLASE ASTRAZENECA AB (SE) 2003-11-13 WO disclosed
US-20020183335-A1 Administering disubstituted pyrimidine-5-carboxamide derivatives for therapy of disorders responsive to the modulation of the potassium channels BRISTOL-MYERS SQUIBB COMPANY 2002-12-05 US disclosed
US-20020169318-A1 Novel thrombin inhibitors ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2002-11-14 US disclosed
US-6444817-B1 ANTICOAGULANTS ABBOTT LABORATORIES 2002-09-03 US disclosed
WO-2002066036-A1 2,4-DISUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-29 WO disclosed
US-6030972-A 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) BASF AKTIENGESELLSCHAFT (DE) 2000-02-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217702-A1 INDOLE DERIVATIVES BDKRB1, BDKRB2, ARRB1 ALDH1A1 1752/4885HSD17B10 2911/4885KDM4E 3663/4885
US-20020183335-A1 Administering disubstituted pyrimidine-5-carboxamide derivatives for therapy of disorders responsive to the modulation of the potassium channels KCNQ5, KCNQ1, KCNQ2 ALDH1A1 2725/4885HSD17B10 4474/4885KDM4E 370/4885
US-20020169318-A1 Novel thrombin inhibitors TFPI, SERPINC1, F11 ALDH1A1 925/4885HSD17B10 1101/4885KDM4E 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.